Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

Br J Haematol. 2020 Sep;190(5):e289-e292. doi: 10.1111/bjh.16286. Epub 2019 Dec 2.
No abstract available

Keywords: daratumumab; dialysis; multiple myeloma; relapse.

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Antibodies, Monoclonal / administration & dosage*
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / mortality*
  • Multiple Myeloma / therapy*
  • Recurrence
  • Renal Dialysis
  • Retrospective Studies
  • Survival Rate

Substances

  • Antibodies, Monoclonal
  • daratumumab